MX2010014524A - Formulaciones de dosificacion solida de telcagepant potásico. - Google Patents

Formulaciones de dosificacion solida de telcagepant potásico.

Info

Publication number
MX2010014524A
MX2010014524A MX2010014524A MX2010014524A MX2010014524A MX 2010014524 A MX2010014524 A MX 2010014524A MX 2010014524 A MX2010014524 A MX 2010014524A MX 2010014524 A MX2010014524 A MX 2010014524A MX 2010014524 A MX2010014524 A MX 2010014524A
Authority
MX
Mexico
Prior art keywords
oxo
potassium
dosage
pharmaceutical formulation
formulation
Prior art date
Application number
MX2010014524A
Other languages
English (en)
Spanish (es)
Inventor
Majid Mahjour
Dan Zhang
Aaron J Moment
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2010014524A publication Critical patent/MX2010014524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2010014524A 2008-06-30 2009-06-29 Formulaciones de dosificacion solida de telcagepant potásico. MX2010014524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13354208P 2008-06-30 2008-06-30
PCT/US2009/049009 WO2010002763A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Publications (1)

Publication Number Publication Date
MX2010014524A true MX2010014524A (es) 2011-02-24

Family

ID=41057505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014524A MX2010014524A (es) 2008-06-30 2009-06-29 Formulaciones de dosificacion solida de telcagepant potásico.

Country Status (16)

Country Link
US (1) US20100009967A1 (enExample)
EP (1) EP2303238A1 (enExample)
JP (2) JP2011526909A (enExample)
KR (1) KR20110025926A (enExample)
CN (1) CN102076330A (enExample)
AR (1) AR072395A1 (enExample)
AU (1) AU2009267145A1 (enExample)
CA (1) CA2728547A1 (enExample)
CR (1) CR20110038A (enExample)
DO (1) DOP2010000409A (enExample)
IL (1) IL209833A0 (enExample)
MX (1) MX2010014524A (enExample)
RU (1) RU2011103170A (enExample)
SV (1) SV2010003774A (enExample)
TW (1) TW201004954A (enExample)
WO (1) WO2010002763A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5243548B2 (ja) * 2007-10-25 2013-07-24 プロテウス デジタル ヘルス， インコーポレイテッド 情報システムのための流体伝達ポート
EP2249833B1 (en) * 2008-02-05 2012-10-17 Merck Sharp & Dohme Corp. Prodrugs of cgrp receptor antagonist
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
ATE209491T1 (de) * 1997-03-13 2001-12-15 Hexal Ag Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AU2007238896A1 (en) * 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. CGRP antagonist salt
CA2662748A1 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Also Published As

Publication number Publication date
CA2728547A1 (en) 2010-01-07
CN102076330A (zh) 2011-05-25
AU2009267145A1 (en) 2010-01-07
TW201004954A (en) 2010-02-01
EP2303238A1 (en) 2011-04-06
RU2011103170A (ru) 2012-08-10
CR20110038A (es) 2011-03-16
WO2010002763A1 (en) 2010-01-07
AR072395A1 (es) 2010-08-25
JP2011526909A (ja) 2011-10-20
JP2011246478A (ja) 2011-12-08
KR20110025926A (ko) 2011-03-14
IL209833A0 (en) 2011-02-28
US20100009967A1 (en) 2010-01-14
SV2010003774A (es) 2011-03-23
DOP2010000409A (es) 2011-02-15

Similar Documents

Publication Publication Date Title
KR100738861B1 (ko) 베타-카르볼린 약학 조성물
HK1044277A (en) Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
JP2013163691A (ja) テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
KR20060019639A (ko) 발데콕시브 조성물
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
WO2004054574A1 (ja) 経口固形医薬
US10085991B2 (en) Formulation inhibiting effects of low acid environment
MX2010014524A (es) Formulaciones de dosificacion solida de telcagepant potásico.
KR102486126B1 (ko) 알펠리십을 포함하는 제약 조성물
TWI222883B (en) Pharmaceutical mixture comprising a combination of a profen and other active compounds
CN104644595A (zh) 一种含有氯吡格雷的固体药物组合物
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
US20130237550A1 (en) Arylvinylazacycloalkane compounds for constipation
WO2025218797A1 (zh) 一种胶囊或固体制剂及其应用
TWI484955B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
TWI462925B (zh) 治療２型糖尿病的藥物組合物
CN114917213A (zh) 包含阿米替林的精神疾病治疗剂和治疗精神疾病的方法
JP2010100550A (ja) 医薬組成物

Legal Events

Date Code Title Description
FA Abandonment or withdrawal